Drugs.com New Drug ApplicationsOriginal article
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
NDA FilingDeucrictibant IRPositive
AI Analysis
Summary
Pharvaris announced FDA acceptance of a new drug application for Deucrictibant IR for on-demand treatment of hereditary angioedema attacks, a rare disease. The acceptance moves the oral bradykinin B2 receptor antagonist forward in the regulatory process.
Outcome Details
FDA accepted new drug application
Importance:7/10
Sentiment:
0.70
regulatoryNDA acceptancerare diseasebradykinin antagonisthereditary angioedema
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on July 6, 2026 9:07 PM